Neurocrine Biosciences will purchase rare disease specialist Soleno Therapeutics for $2.9 billion in cash, company statements confirmed on Monday. The acquisition marks a strategic move by the neuroscience-focused drugmaker into metabolic disease treatments.
Under the terms announced, Neurocrine has proposed $53 for each outstanding share of Soleno, a level that corresponds to approximately a 34% premium relative to Soleno's most recent closing price. Prior to trading being halted, Soleno shares rose by more than 30% in premarket activity after initial reporting of the deal.
The transaction brings Vykat XR into Neurocrine's portfolio. Vykat XR is the first medicine approved in the United States to treat hyperphagia associated with Prader-Willi syndrome, a rare genetic condition. Hyperphagia - defined in the announcement as persistent and intense feelings of hunger - is the defining symptom of Prader-Willi syndrome and can lead to severe obesity along with physical, mental and behavioral complications.
Context on investor tools noted in the announcement
The announcement also referenced an AI-driven analytics product that evaluates Neurocrine alongside thousands of other companies using more than 100 financial metrics. That product, described in the materials, claims to generate stock ideas by assessing fundamentals, momentum and valuation without human bias. The materials cited past winners identified by that system, including Super Micro Computer with a gain of 185% and AppLovin with a gain of 157%.
The materials invited investors to check whether Neurocrine (NBIX) is currently featured in any of the product's strategies or whether there are alternative opportunities in the same sector.
Implications and immediate market reaction
The deal is a clear move for Neurocrine into treatments that address metabolic and rare-disease indications. The immediate market response included a significant premarket rise in Soleno shares followed by a halt in trading. Beyond the headline purchase price and per-share offer, the announcement did not provide additional detail on integration plans or longer-term commercial expectations for Vykat XR.